Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Sabini

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
European Thyroid Journal|October 27, 2017
Does Graves' Orbitopathy Ever Disappear? Answers to an Old QuestionElena Sabini, Marenza Leo, Barbara Mazzi, et al.
Endocrinology|July 31, 2021
Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse ModelFabiana Pani, Yoshinori Yasuda, Giulia Di Dalmazi, et al.
The Lancet. Diabetes & Endocrinology|September 30, 2021
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trialGiulia Lanzolla, Elena Sabini, Marenza Leo, et al.
Endocrine|October 7, 2016
Natural history of graves' orbitopathy after treatmentFrancesca Menconi, Marenza Leo, Elena Sabini, et al.
JCI Insight|August 1, 2024
HIF1 activation safeguards cortical bone formation against impaired oxidative phosphorylationMohd P Khan, Elena Sabini, Katherine Beigel, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2024
Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiencyGiulia Lanzolla, Elena Sabini, Katherine Beigel, et al.
Oncotargets and Therapy|November 2, 2016
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerLoredana Lorusso, Letizia Pieruzzi, Agnese Biagini, et al.
Journal of Endocrinological Investigation|March 21, 2025
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimusSimone Comi, Giada Cosentino, Elena Sabini, et al.
Nature Reviews. Endocrinology|July 15, 2017
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapiesEleonora Molinaro, Cristina Romei, Agnese Biagini, et al.
Thyroid : Official Journal of the American Thyroid Association|January 17, 2018
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional StudyElena Sabini, Barbara Mazzi, Maria Antonietta Profilo, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
European Thyroid Journal|October 27, 2017
Does Graves' Orbitopathy Ever Disappear? Answers to an Old QuestionElena Sabini, Marenza Leo, Barbara Mazzi, et al.
Endocrinology|July 31, 2021
Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse ModelFabiana Pani, Yoshinori Yasuda, Giulia Di Dalmazi, et al.
The Lancet. Diabetes & Endocrinology|September 30, 2021
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trialGiulia Lanzolla, Elena Sabini, Marenza Leo, et al.
Endocrine|October 7, 2016
Natural history of graves' orbitopathy after treatmentFrancesca Menconi, Marenza Leo, Elena Sabini, et al.
JCI Insight|August 1, 2024
HIF1 activation safeguards cortical bone formation against impaired oxidative phosphorylationMohd P Khan, Elena Sabini, Katherine Beigel, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2024
Pharmacological inhibition of HIF2 protects against bone loss in an experimental model of estrogen deficiencyGiulia Lanzolla, Elena Sabini, Katherine Beigel, et al.
Oncotargets and Therapy|November 2, 2016
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerLoredana Lorusso, Letizia Pieruzzi, Agnese Biagini, et al.
Journal of Endocrinological Investigation|March 21, 2025
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimusSimone Comi, Giada Cosentino, Elena Sabini, et al.
Nature Reviews. Endocrinology|July 15, 2017
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapiesEleonora Molinaro, Cristina Romei, Agnese Biagini, et al.
Thyroid : Official Journal of the American Thyroid Association|January 17, 2018
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional StudyElena Sabini, Barbara Mazzi, Maria Antonietta Profilo, et al.
Pageof 3